Brief: Marinus Pharmaceuticals Reports Preliminary Q4 And FY2023 Ztalmy® Net Product Revenue
04/01/2024 12:47
Jan 4 (Reuters) - Marinus Pharmaceuticals Inc MRNS.O :
* MARINUS PHARMACEUTICALS REPORTS PRELIMINARY FOURTH QUARTER
AND
FULL YEAR 2023 ZTALMY® NET PRODUCT REVENUE AND PROVIDES BUSINESS
UPDATE
* PROJECTED FULL YEAR 2024 U.S. ZTALMY NET PRODUCT REVENUE
OF
BETWEEN $32 AND $34 MILLION
* CASH RUNWAY PROJECTED INTO Q4 2024 WITH PRELIM UNAUDITED
CASH,CASH EQUIVALENTS,SHORT-TERM INVESTMENTS OF $150.3 MILLION
AS OF DEC 31, 2023
Source text for Eikon: ID:nBw1kd3Jma
Further company coverage: MRNS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marinus Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Axsome Therapeutics, Ducommun, Vacasa
Brief: Immedica To Acquire Biopharmaceutical Company Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Appfolio, S&P Global, Uber
U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group